Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-10-2008 | Original Paper

Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival

Authors: Gaosi Xu, Jiangguo Zhang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2008

Abstract

Objective

To elucidate if Fas/FasL signal pathway participates in the immune escape of tumor cells, and if contemporarily preventing Fas/FasL and TNF-induced apoptosis is better for immune cells survival than just blocking Fas/FasL-induced apoptotic signal.

Methods

Suppression of FasL expression in mouse H22 hepatocellular cancer cells by siRNA technique. Wild-type Ad5 14.7K gene was amplified by PCR and transduced into Jurkat T cells. Detecting apoptosis of target Jurkat cells by Flow Cytometry. Detection of TNF-α in the culture supernatant of H22 cells by ELISA. FasL and 14.7K gene expression in stably transfected or transduced clones were determined by western blotting.

Results

FasL expression in H22 cells was down-regulated following stable transfection with a plasmid encoding antisense FasL cDNA. Down-regulation of FasL expression in H22 cells had no effect on tumor growth in vitro. There was an apparent decrease in the number of apoptotic Jurkat T cells following coculture with transfected H22 cells, relative to coculture with FasL-expressing untransfected cells. Compared with untransduced Jurkat cells, apoptotic rates in 14.7K transduced Jurkat cells were significantly reduced in three different E/T ratios (P < 0.01), respectively.

Conclusions

Fas/FasL signal pathway participated in the immune escape of tumor cells by inducing immune cells apoptosis. Reducing the expression of FasL in tumor cells can decrease the apoptotic rate of immune cells. Further blocking of apoptotic signal pathway of immune cells by preventing TNF-induced apoptosis can increase the survival of immune cells.

Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844–854PubMedCrossRef

Arai H, Chan SY, Bishop DK et al (1997) Inhibition of the alloantibody response by CD95 ligand. Nat Med 3:843–848PubMedCrossRef

Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281:1305–1308PubMedCrossRef

Aubry JP, Blaecke A, Lecoanet-Henchoz S et al (1999) Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry 37:197–204PubMedCrossRef

Cefai D, Favre L, Wattendorf E et al (2001a) Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model. Int J Cancer 91:529–537PubMedCrossRef

Cefai D, Schwaninger R, Balli M et al (2001b) Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy. Cell Death Differ 8:687–695PubMedCrossRef

Chen P, Tian J, Kovesdi I et al (1998) Interaction of the adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis. J Biol Chem 273:5815–5820PubMedCrossRef

Chinnadurai G. (1998) Control of apoptosis by human adenovirus genes. Semin Virol 8:399–408CrossRef

Clarke P, Meintzer S, Gibson S et al (2000) Reovirus-induced apoptosis is mediated by TRAIL. J Virol 74:8135–8139PubMedCrossRef

Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4:11–22PubMedCrossRef

Elsing A, Burgert HG (1998) The adenovirus E3/10.4K–14.5K proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization. Proc Natl Acad Sci USA 95:10072–10077PubMedCrossRef

Falcone M, Sarvetnick N (1999) Cytokines that regulate autoimmune responses. Curr Opin Immunol 11:670–676PubMedCrossRef

Fanger N, Maliszewski C, Schooley K et al (1999) Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190:1155–1164PubMedCrossRef

Ferguson TA, Green DR (2001) Fas ligand and immune privilege: the eyes have it. Cell Death Differ 8:771–772PubMedCrossRef

Flavio SO, Mercedes NL, Ariadna MN (2007) Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 18:171–182CrossRef

Gooding LR, Elmore LW, Tollefson AE et al (1988) A 14, 700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell 53:341–346PubMedCrossRef

Gooding LR, Sofola IO, Tollefson AE et al (1990) The adenovirus E3–14.7K protein is a general inhibitor of tumor necrosis factor-mediated cytolysis. J Immunol 145:3080–3086PubMed

Griffith TS, Wiley SR, Kubin M et al (1999) Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189:1343–1353PubMedCrossRef

Horton TM, Ranheim TS, Aquino L et al (1991) Adenovirus E3 14.7K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis. J Virol 65:2629–2639PubMed

Jeremias I, Herr I, Boehler T et al (1998) TRAIL/Apo2-ligand-induced apoptosis in human T cells. Eur J Immunol 28:143–152PubMedCrossRef

Khar A, Varalakshmi C, Pardhasaradhi BV et al (1998) Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing fas-ligand: a mechanism of immune evasion. Cell Immunol 189:85–91PubMedCrossRef

Krammer PH (2000) CD95’s deadly mission in the immune system. Nature 407:789–795PubMedCrossRef

Mahr JA, Gooding LR (1999) Immune evasion by adenoviruses. Immunol Rev 168:121–130PubMedCrossRef

Niehans GA, Brunner T, Frizelle SP et al (1997) Human lung carcinomas express Fas ligand. Cancer Res 57:1007–1012PubMed

O’Connell J, O’Sullivan GC, Collins JK et al (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075–1082PubMedCrossRef

Schmid S, Hearing P (1999) Adenovirus DNA packaging. Construction and analysis of viral mutants. In: Wold WS (ed) Adenovirus methods and protocols. Humana Press, Totowa, pp 47–59

Schneider-Brachert W, Tchikov V, Merkel O (2006) Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism. J Clin Invest 116:2901–2913PubMedCrossRef

Schulze-Osthoff K, Ferrari D, Los M et al (1998) Apoptosis signaling by death receptors. Eur J Biochem 254:439–459PubMedCrossRef

Song E, Chen J, Ouyang N et al (2001) Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 85:1047–1054PubMedCrossRef

Teodoro JG, Branton PE (1997) Regulation of apoptosis by viral gene products. J Virol 71:1739–1746PubMed

Tollefson AE, Hermiston TW, Lichtenstein DL et al (1998) Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 392:726–730PubMedCrossRef

Vidalain P, Azocar O, Lamouille B et al (2000) Measles virus induces functional TRAIL production by human dendritic cells. J Virol 74:556–559PubMedCrossRef

Walczak H, Miller RE, Ariail K et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosisinducing ligand in vivo. Nat Med 5:157–163PubMedCrossRef

White E (1998) Regulation of apoptosis by adenovirus E1A and E1B oncogenes. Semin Virol 8:505–513CrossRef

Windheim M, Hilgendorf A, Burgert HG (2004) Immune evasion by adenovirus E3 proteins: exploitation of intracellular trafficking pathways. Curr Top Microbiol Immunol 273:79–85

Title: Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival
Authors: Gaosi Xu
Jiangguo Zhang
Publication date: 01-10-2008
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2008
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-008-0393-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival

Abstract

Objective

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2008

Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype

Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases

Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy

Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy

The role of omentectomy during the surgical staging in patients with clinical stage I endometrioid adenocarcinoma

FISH analysis of chromosomes 3 and 6 on fine needle aspiration biopsy samples identifies distinct subgroups of uveal melanomas

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page